Previous close | 0.6000 |
Open | 0.6000 |
Bid | 0.0000 |
Ask | 5.0000 |
Strike | 10.00 |
Expiry date | 2024-08-16 |
Day's range | 0.6000 - 0.6000 |
Contract range | N/A |
Volume | |
Open interest | 9 |
LA JOLLA, Calif., June 10, 2024--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive interim results from its ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 years old with Developmental and Epileptic Encephalopathies.
LA JOLLA, Calif., June 03, 2024--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to four new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 92,000 shares of its common stock (the "Common Stock") as inducements material t
We can readily understand why investors are attracted to unprofitable companies. Indeed, Longboard Pharmaceuticals...